Previous Close | 2.41 |
1-Year Change | -76.19% |
6-Months Change | -59.97% |
3-Months Change | -36.41% |
Moving Avg (50d) | 3.2582 |
Moving Avg (200d) | 5.2384 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 196.8M |
Beta (3-Years) | 1.99 |
Revenue Growth (ttm) | -4.03% |
Net Profit Margin (ttm) | -792.7% |
Return On Assets (ttm) | -38.66% |
EPS (ttm) | -2.7 |
PE Ratio (ttm) | -0.89 |
Dividend Yield | % |
Asset Description: | Editas Medicine, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-08 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
2.458 | 2.531 | 2.579 | 2.651 | 2.772 | 2.892 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |